论文部分内容阅读
FDA于2008-09-12批准修改西妥昔单抗(Erbitux)静脉输液标签的安全性标识,以警示其可能引发严重输液反应和皮肤毒性危险。
The FDA approved the revision of the safety label for intravenous infusion of cetuximab (Erbitux) on September 12, 2008 to warn of the potential for serious infusion reactions and the risk of skin toxicity.